Hansa Biopharma is preparing to submit an application to the European Medicines Agency (EMA) to convert the conditional marketing authorisation of its groundbreaking desensitisation therapy, Idefirix (imlifidase), into full approval. This pivotal move follows the successful completion of a crucial post-authorisation efficacy study (PAES) that demonstrated exceptional one-year graft failure-free survival rates in highly sensitized patients undergoing kidney transplantation.
The results from the open-label, multi-centre PAES, known as the 20-HMedIdeS-19 study (NCT05369975), have provided compelling evidence of Idefirix’s significant clinical benefit and robust safety profile. This achievement marks a critical milestone not only for Hansa Biopharma but also for a vulnerable patient population facing profound challenges in accessing life-saving kidney transplants due to immunological barriers.
Landmark Study Demonstrates Overwhelming Efficacy in Highly Sensitized Patients
The PAES was meticulously designed to evaluate the one-year graft failure-free survival and overall patient survival in individuals who had undergone human leukocyte antigen (HLA)-incompatible kidney transplantation. These patients, often deemed untransplantable due to the presence of pre-formed antibodies against donor antigens, received desensitisation treatment with Idefirix prior to their transplant.
A total of 51 patients were enrolled in the study, receiving Idefirix across 22 transplant centres spanning 11 countries within the European Union (EU) and the United Kingdom. The study’s primary endpoint, one-year graft failure-free survival, was impressively met, with a remarkable 90% of patients achieving this critical outcome. This signifies that the majority of patients who received Idefirix were able to retain their transplanted kidney and remain free from graft failure one year post-transplantation.
Beyond the primary endpoint, the secondary endpoints further underscored the profound impact of Idefirix. The study reported a mean estimated glomerular filtration rate (eGFR) of 52.4 mL/min/1.73m², indicating preserved renal function one year after transplantation. Furthermore, graft survival remained exceptionally high at 92%, and patient survival reached an impressive 98%. These figures represent a significant advancement in transplant outcomes for a population that historically faced extremely poor prognoses.
The safety profile of Idefirix, as assessed in the PAES, was found to be consistent with previously observed data from earlier clinical trials. The drug was generally well tolerated, with a retention rate exceeding 94%, suggesting good patient adherence and minimal treatment-related discontinuations. This reassuring safety data further bolsters the case for its widespread adoption and full regulatory approval.
Chronology of Idefirix Development and Regulatory Journey
The path to this significant juncture for Idefirix has been marked by strategic development and a commitment to addressing unmet medical needs.
- Conditional Approval: Idefirix initially received conditional marketing authorisation in the European Union. This accelerated pathway is typically granted for medicines that address unmet medical needs and where the benefit of immediate availability outweighs the risk of later withdrawal. A condition of this approval was the successful completion of the PAES to confirm its clinical utility and safety.
- Post-Authorisation Efficacy Study (PAES): The 20-HMedIdeS-19 study was initiated as a direct requirement of the EMA to fulfil the conditions for full marketing authorisation. This study’s design focused on real-world evidence in a challenging patient population, providing critical data for regulatory decision-making.
- Successful PAES Completion: The recently announced positive results from the PAES form the cornerstone of Hansa Biopharma’s application for full approval. The achievement of primary and secondary endpoints has provided the necessary robust data to support this regulatory transition.
- Upcoming EMA Submission: Following the successful conclusion of the PAES, Hansa Biopharma is now poised to formally apply to the EMA for the conversion of Idefirix’s conditional approval into full marketing authorisation. The company has indicated its intention to submit this application by the end of the current year.
- Strategic Rights Transfer: In parallel with the regulatory progress, a significant development has occurred regarding the commercial rights to Idefirix. This month, SERB Pharmaceuticals entered into an agreement to acquire exclusive development and commercialisation rights for Idefirix from Hansa Biopharma. This transaction, valued at €115 million ($133.6 million), encompasses the EU, Iceland, Liechtenstein, Norway, Switzerland, the UK, and the Middle East and North Africa (MENA) region. This strategic move suggests a strong confidence in Idefirix’s future market potential by SERB Pharmaceuticals.
- US Regulatory Pathway: While Idefirix is currently not approved for use in the United States, Hansa Biopharma has proactively pursued regulatory engagement. In February 2026, the company submitted a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA). The Prescription Drug User Fee Act (PDUFA) target action date for this review is set for December 19, 2026, indicating the FDA’s ongoing evaluation of the drug for the US market.
Supporting Data: A Deep Dive into the Clinical Evidence
The strength of Hansa Biopharma’s application for full approval rests on the comprehensive data generated by the PAES. The study’s design and execution were critical in demonstrating Idefirix’s efficacy and safety in a population with a high unmet medical need.
Key Data Points from the PAES:
- Patient Population: Highly sensitized patients undergoing HLA-incompatible kidney transplantation following desensitisation with Idefirix. This group typically faces significant immunological barriers, making them high-risk candidates for transplant rejection.
- Number of Patients Enrolled: 51
- Transplant Centres: 22
- Countries: 11 EU countries and the UK
- Primary Endpoint: One-year graft failure-free survival.
- Result: 90% of patients achieved this outcome. This is a critical indicator of the therapy’s ability to prevent the loss of the transplanted organ.
- Secondary Endpoints:
- Renal Function (eGFR) at One Year:
- Result: 52.4 mL/min/1.73m². This demonstrates that the transplanted kidneys are functioning effectively, preserving the patient’s quality of life and overall health.
- Graft Survival at One Year:
- Result: 92%. A high graft survival rate is paramount in kidney transplantation, signifying the long-term success of the procedure.
- Patient Survival at One Year:
- Result: 98%. This exceptionally high survival rate underscores the life-saving potential of Idefirix in enabling successful transplantation for patients who would otherwise have limited options.
- Renal Function (eGFR) at One Year:
- Safety Profile:
- General Tolerability: Idefirix was generally well tolerated.
- Consistency with Prior Data: The safety profile observed in the PAES was consistent with previous clinical trial experience, providing reassurance to clinicians and regulators.
- Retention Rate: Above 94%. This high retention rate indicates that patients were able to complete the prescribed treatment regimen, minimizing treatment interruptions and maximizing potential benefits.
The statistical significance and clinical relevance of these data points are expected to be compelling for the EMA in their review process for full marketing authorisation.
Official Responses and Strategic Outlook
The positive outcomes of the PAES have elicited strong endorsements from key stakeholders.
Hansa Biopharma CEO, Renée Aguiar-Lucander, expressed her enthusiasm: "These positive results represent a significant milestone for Idefirix and for Hansa. The one-year graft failure-free survival observed in this highly sensitised patient population confirms the clinical benefit of Idefirix and demonstrates expected efficacy outcomes supported by a safety profile consistent with prior clinical experience."
Aguiar-Lucander’s statement highlights the dual triumph: achieving the study’s objectives and validating the therapeutic potential of Idefirix. This sentiment is echoed by the impending acquisition by SERB Pharmaceuticals, which signals a robust belief in the drug’s commercial viability and future growth.
The strategic decision by SERB Pharmaceuticals to acquire the rights to Idefirix underscores the perceived value of this therapy. Their investment suggests confidence in the ongoing regulatory processes in Europe and potentially other key markets. The comprehensive nature of the deal, covering a significant geographical territory, indicates a long-term commitment to making Idefirix accessible to a wider patient base.
Broader Implications and Future Potential
The potential full approval of Idefirix by the EMA and its ongoing evaluation by the FDA have far-reaching implications for organ transplantation and beyond.
- Transforming Transplant for Highly Sensitized Patients: For individuals with pre-existing antibodies against donor organs, the transplant landscape has historically been fraught with challenges and limited options. Idefirix offers a paradigm shift, enabling successful transplantation for a significant proportion of these patients who were previously considered untransplantable. This not only extends lives but also drastically improves the quality of life by freeing patients from the burdens of dialysis and the constant search for a compatible donor.
- Advancements in Gene Therapy: Beyond its primary indication in organ transplantation, Idefirix has demonstrated promising utility as a pre-treatment agent in gene therapy. In a collaborative effort with Sarepta Biosciences and Roche for their gene therapy Elevidys (delandistrogene moxeparvovec), Idefirix has been investigated in Phase I studies. Its ability to reduce patients’ immunoglobulin G (IgG) antibodies has proven crucial in enabling eligibility for gene therapy treatment, thereby expanding the potential application of this innovative treatment modality. This dual-use potential significantly enhances the overall value proposition of Idefirix.
- Economic Impact and Market Potential: The successful transition to full marketing authorisation will unlock significant commercial potential for Idefirix. The acquisition by SERB Pharmaceuticals is a testament to this. As the prevalence of organ failure continues to rise globally, therapies that can expand the donor pool and improve transplant outcomes will be in high demand. Idefirix is strategically positioned to meet this growing need.
- Regulatory Precedent: The successful navigation of the conditional approval and subsequent PAES by Hansa Biopharma sets a positive precedent for other innovative therapies targeting rare diseases or specific patient subgroups with unmet medical needs. It demonstrates the EMA’s commitment to facilitating access to potentially life-saving treatments while ensuring rigorous scientific validation.
- Global Health Equity: While the current regulatory focus is on Europe and the US, the broader geographic coverage of the SERB Pharmaceuticals agreement, including the MENA region, hints at a commitment to global health equity. Making such advanced therapies accessible in diverse healthcare settings is crucial for addressing disparities in organ transplantation access worldwide.
In conclusion, the upcoming application for full marketing authorisation of Idefirix by Hansa Biopharma represents a pivotal moment in organ transplantation medicine. The compelling data from the PAES, coupled with the strategic commercial partnership with SERB Pharmaceuticals, positions Idefirix to become a cornerstone therapy for highly sensitized patients and a valuable tool in the evolving landscape of gene therapy. The successful regulatory journey of Idefirix underscores the power of dedicated research and development in overcoming significant medical challenges and delivering life-changing innovations to patients in need.
About the Author
